Bris­tol My­ers Squibb spells out OS ben­e­fit of Op­di­vo/Yer­voy com­bo plus 'lim­it­ed' chemother­a­py — is it enough to change prac­tice?

Nor­mal­ly when a PD-1 in­hibitor is giv­en with chemother­a­py as a first-line treat­ment of non-small cell lung can­cer — a reg­i­men pop­u­lar­ized by Mer­ck and its mar­ket-lead­ing check­point drug Keytru­da — pa­tients go through four cy­cles of chemo, some­times more as main­te­nance. Bris­tol My­ers Squibb set out to test in CHECK­MATE-9LA whether two cy­cles plus a com­bi­na­tion of Op­di­vo and Yer­voy would do the job. At AS­CO, they will be mak­ing the case that it does.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER